Vertex Pharmaceuticals
NASDAQ:VRTXBiotechBoston, Massachusetts, United States · Est. 1989 · 2,400 employees
Vertex Pharmaceuticals is a global biotechnology company that discovers, develops, and commercializes innovative therapies for serious diseases, with a primary focus on cystic fibrosis and other rare genetic conditions.
15
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
12
Indications↗
Distinct diseases across all programs
272
Clinical Trials↗
All sponsored trials (all statuses)
23
Orange Book Patents
Across 3 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
15 drugs in development
Phase 36
Phase 24
Phase 16
Preclinical1
By Therapeutic Area
top 5
Rare Disease
424%
Metabolic & Endocrine
318%
Nephrology
212%
Neurology
212%
Hematology
16%
R&D Momentum
68/100
Pipeline Velocity
42/100
Trial Completion Rate
90/100
Pipeline Concentration
20/100
Pipeline Freshness
78/100
Strategic Signals
- ↗Active in Hematology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Oct 31, 2026
Recruiting
A Phase 1, Open-Label, Mass Balance Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 Following Single Oral Administration in Healthy Subjects
Oct 31, 2026
Active, not recruiting
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
Oct 31, 2026
Recruiting
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
Oct 30, 2026
Active, not recruiting
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults With Generalized Myasthenia Gravis
Oct 29, 2026
Active, not recruiting
A Phase 4, Double-blind, Sequential Cohort Study of Pain Treatment and Recovery After Total Knee Arthroplasty
Oct 28, 2026
Active, not recruiting
A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Relative Bioavailability of a Tablet Formulation of VX-581 in Healthy Adult Subjects
Oct 28, 2026
Active, not recruiting
A Phase 3 Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects With Non-F508del CFTR Genotypes
Oct 27, 2026
Active, not recruiting
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease
Oct 27, 2026
Active, not recruiting
A Study to Determine the Prevalence and Clinical Characteristics Associated With PKD1 Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Details
Company Info
Company Overview
$67.0B
Mkt Cap
$7.7B
Revenue
—
Cash
CEOReshma Kewalramani
Founded1989
Employees2,400
HQBoston, Massachusetts, United States
ExchangeNASDAQ:VRTX
Websitevrtx.com
LinkedInCompany Page
Therapeutic Focus
Infectious DiseaseOtherHematologyGastroenterologyNeurologyMusculoskeletalCardiovascularRare DiseaseRespiratoryImmunologyMetabolic & EndocrineNephrologyOncology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Hematology
Beta-Thalassemia
CTX001Phase 3
Sickle Cell Disease
CTX001Phase 3
Metabolic & Endocrine
Nephrology
Neurology
Rare Disease
Showing 15 of 19 programs
Regulatory
Regulatory Timeline
20111 event
FDAMay 23
Incivek — INCIVEK
Application NDA201917 (NDA)
20121 event
FDAJan 31
Kalydeco — KALYDECO
Application NDA203188 (NDA)
20231 event
FDAMay 3
Kalydeco — KALYDECO
Application NDA207925 (NDA)
20251 event
FDAJan 30
Journavx — JOURNAVX
Application NDA219209 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)